Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Meta Expands AI Training With Employee Activity Tracking Tools 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
 - EconoTimes)
NEW YORK, March 04, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against PTC Therapeutics (“PTC” or the “Company”) (Nasdaq:PTC) in the United States District Court for the District of New Jersey on behalf of a class consisting of all persons or entities who purchased PTC securities between May 6, 2014 and February 23, 2016, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that during the Class Period, Defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects and that as a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period. According to the Complaint, on February 23, 2016, PTC announced that it received a Refuse to File letter from the United States Food and Drug Administration (“FDA”) regarding PTC’s New Drug Application (“NDA”) for Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”). The FDA stated in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review.
On this news, shares of PTC plummeted over 61%, closing at $10.84 per share on February 23, 2016, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than May 2, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
